Title page

2	Acceptability of fixed-dose combination treatments for hypertension in Kenya: a qualitative
3	study using the Theoretical Framework of Acceptability.
4	Daniel Mbuthia ¹ , Ruth Willis ² , Mary Gichagua ³ , Jacinta Nzinga ¹ , Peter Mugo ^{1†} , Adrianna
5	Murphy* ²
6	1 Health Economics Research Unit, KEMRI-Wellcome Trust Research Program, Nairobi, Kenya
7	2 London School of Hygiene and Tropical Medicine, London, UK
8	3 Department of Health, Kiambu, Kenya
9	† Deceased
10	
11	
12	*Corresponding author
13	Email: Adrianna.Murphy@lshtm.ac.uk
14	
15	Acknowledgement
16	We acknowledge UKRI for funding this research study through the UKRI Future Research Leader
17	Fellowship grant awarded to Dr Adrianna Murphy by the UK Research and Innovation fund,
18	grant number MR/T042508/1. The funding sources had no role in the study design, writing of

19	the report and in the decision to submit the manuscript for publication. We would also like to
20	acknowledge all the healthcare workers, patients and caregivers who participated in the study
21	
22	Conflict of interest
23	The authors declare that they have no conflicts of interest.
24	
25	
26	
27	
28	
29	
30	

Acceptability of fixed-dose combination treatment for hypertension in

Kenya: a qualitative study using the Theoretical Framework of

Acceptability

Abstract

32

33

34

35

36

37

38

39

40

42

43

44

45

46

48

49

Background

Fixed-dose combinations (FDCs) - 2-3 anti-hypertensive medications in a single pill - have the

potential to improve hypertension treatment and outcomes. Yet, they are not widely

implemented. Factors undermining implementation remain unknown, particularly in sub-

Saharan Africa, where hypertension is a major cause of disease burden and is poorly treated.

Methods

41 We used in-depth semi-structured interviews to explore the acceptability of FDCs among

patients, caregivers, and healthcare workers. We interviewed a total of 58 participants across

four purposively selected health facilities in one county in Kenya. Data were analyzed using

abductive thematic analysis approach, and emergent themes categorized according to the

Theoretical Framework of Acceptability.

Results

47 Overall, FDCs are potentially acceptable to all participant groups. Acceptability is supported by a

perception of FDCs as a means of reducing treatment burden (for patients and healthcare

workers) and improving treatment adherence, and patients' deferral to and trust in health

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

workers. Acceptability among health workers may be undermined by variable levels of FDC coherence, concerns among health workers about FDCs as an "inflexible" treatment that does not allow dose titration or identifying causes of side effects, and concerns about consistent availability and affordability of FDCs in Kenya. Conclusion FDCs are a potentially acceptable treatment approach for hypertension in Kenya. Efforts to improve acceptability and thus implementation of FDCs in Kenya should consider improving understanding of treatment and strengthening the capacity of all health worker cadres to appropriately prescribe, inform about, and support adherence to FDCs. These efforts must align with work to address upstream health system factors such as poor availability and affordability. Key words Hypertension Fixed dose combinations Implementation Research Acceptability Sub Saharan Africa

Background

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Cardiovascular disease (CVD) is the leading cause of death globally, accounting for almost 18 million deaths annually (1). Of these, over 10 million CVD deaths are due to uncontrolled hypertension (blood pressure > 140/90 mm Hg). Most of these deaths occur in low- and middleincome countries (LMICs) (1) and are in part due to low rates of treatment. In Kenya, for example, the prevalence of hypertension among people aged 18-69 years is estimated at 24.5% (2), and only 3% of those diagnosed have their blood pressure controlled (3). This gap in treatment has been attributed to inconsistent availability and affordability of antihypertensives (4), poor adherence to prescribed treatment, (5) the high number and diversity of anti-hypertensive medication treatment options, which can make treatment complex (6), and 'therapeutic inertia', or the failure of physicians to initiate or intensify therapy when BP remains elevated (7). Despite evidence that 75-80% of hypertensive patients require multiple classes of drugs to effectively control their blood pressure, many receive monotherapy (one drug) (8). Fixed-dose combination treatments: a potential solution for bridging the treatment gap Fixed-dose combination (FDC) treatments – a combination of 2-3 anti-hypertensive medications in a single pill – offer one potential tool to address the gap in hypertension treatment in LMIC settings. FDCs can enhance patient compliance by reducing the pill burden, making it easier for patients to adhere to their treatment regimen compared to taking multiple single-molecule pills (9). FDCs have been shown to have other benefits including faster achievement of blood pressure targets (10), fewer CVD events (11), reductions in therapeutic inertia (12, 13), and reduction in healthcare costs (14). In 2019, the World Health Organization (WHO) included FDCs in their

Model Essential Medicines List and released a new guideline in 2021 recommending use of FDCs for treatment of hypertension (15). In Kenya, FDCs for hypertension are authorized for marketing and there are nine FDCs included in the Kenyan National Essential Medicines List (amlodipine + hydrochlorothiazide, amlodipine + indapamide, perindopril + amlodipine, perindopril + amlodipine + indapamide, losartan + hydrochlorothiazide, lisinopril + hydrochlorothiazide, telmisartan + amlodipine, telmisartan + hydrochlorothiazide and telmisartan + amlodipine + hydrochlorothiazide) (16) and recommended in the treatment guidelines for hypertension (17). However, uptake of FDCs in LMICs, including in Kenya, has been slow (18).

To inform the development of a strategy to improve implementation of FDCs for treatment of hypertension in Kenya, we aimed to evaluate the acceptability of FDCs for patients with

Methods

Conceptual Framework: Theoretical Framework of Acceptability

hypertension, their caregivers, and healthcare providers.

To conceptualize acceptability of FDC treatments for hypertension, we used the Theoretical Framework of Acceptability (TFA) (19). TFA has been applied in implementation research across a range of settings and health domains, including for a hypertension and CVD management in LMIC settings (20, 21). TFA identifies seven component constructs contributing to acceptability of healthcare interventions. These include: Affective attitude (How an individual feels about the intervention); Burden (The perceived amount of effort that is required to participate in the intervention); Ethicality (The extent to which the intervention has good fit with an individual's value system); Intervention coherence (The extent to which the individual understands the

intervention and how it works); Opportunity costs (The extent to which benefits, values, or profits must be given up to engage in the intervention); Perceived effectiveness (The extent to which the intervention is perceived as likely to achieve its purpose); and Self-efficacy (The individuals' confidence that they can perform the behaviour(s) required to participate in the intervention). Appendix 1 presents our interpretation of each construct for acceptability of FDC treatment for hypertension, which informed our overall study design, data collection tools and analysis.

Study design

We used an explorative qualitative study design. This design allows for in-depth exploration and understanding of a phenomenon when there is limited prior evidence - to the best of our knowledge, this is the first study exploring the acceptability of FDCs for hypertension in Kenya, and only one of the few in the world. We conducted non-participant observation and semi-structured in-depth interviews in Kiambu County, Kenya. Non-participant observation was used to orientate the study team to facility operations and current practices for treatment of patients with hypertension in context, and to inform criteria for selection of participants for semi-structured interviews. Semi-structured interviews were used to explore participant experiences and attitudes in depth.

Study setting

The study was set in one county in order to develop a robust understanding of a specific context (22) to enable identification of both locally specific factors affecting acceptability, and the categories of factors to consider in potential design and scale-up of a subsequent intervention to

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

improve implementation of FDCs. The choice of county was informed by consideration of (i) contextual diversity, to include urban and rural populations from a range of socio-economic situations; (ii) receptiveness of county stakeholders to NCD implementation research, while not being overburdened with ongoing research projects, and (iii) practicality in relation to the operational base of the study team in Nairobi and to national policy stakeholders. Kiambu County is adjacent to Nairobi County in central Kenya, and whilst aggregated county level socio-economic indicators are above the national average, for example overall poverty rate of 20.5% (Kiambu County) compared with 38.6% (national) (23), there is diversity within the county population across 14 urban and rural sub-counties (24)]. The Kenyan public health system is organized in 6 care levels. Treatment of hypertension in public hospitals is mainly delivered at primary healthcare centres (level 3) subcounty hospitals (level 4) and county referral hospitals (level 5) (18). We collected data in four public sector facilities located in three sub-counties, purposively selected with input from county stakeholders to include a range of facility levels, urban/rural and socio-demographically diverse catchment populations. Based on these criteria we selected one county referral hospital (level 5), one subcounty hospital (level 4), and two primary healthcare centres (level 3) serving contrasting urban and rural populations (25). All facilities provide care to people living with hypertension, including prescription of anti-hypertensive medication, through non communicable disease (NCD) or Medical Outpatient Clinics (MOPCs). Specific facilities selected and their characteristics are outlined in Table 1.

Table 1: Study facility characteristics

153

Facility	Characteristics
Health facility 1	Level 4 sub-county referral hospital
	Serves mostly urban population.
	High patient volume
	Medical officers, clinical pharmacists, clinical officers [non-
	physician clinicians], nurses, nutritionists
Health facility 2	Level 3 primary healthcare center
	Serves urban population.
	Low patient volume
	1 Medical officer and 1 clinical officer
Health facility 3	Level 5 county referral hospital
	Serves both urban and rural populations
	Very high patient volume
	Medical consultants, medical officers, clinical pharmacists,
	clinical officers, nurses, nutritionists
Health facility 4	Level 3 primary health center
	Serves rural population

High patient volume

1 nurse supported by 1 community health promoter (CHP)

(often referred to as community health workers in other settings) and occasional locum hire of clinical officer

Participant recruitment

Patients living with hypertension were selected purposively from patient registers to represent a range of categories relevant to experiences of hypertension treatment (age, sex, comorbidities, length of time since diagnosis, caregiver accompaniment) (Table 2). A small number of caregivers (1-2) were recruited from each facility following patient interviews, with prior permission from patients. Healthcare worker participants were purposively selected to ensure inclusion of one member from each staff cadre involved in hypertension treatment at each facility.

Eligible study participants were approached face to face or by telephone (caregivers) and invited to join the study. Participants were provided with a study information sheet [English/Swahili].

DM reviewed the information sheet with each participant and written consent was obtained from all participants. Recruitment at each facility stopped when patients from a pre-specified range of category combinations had been included, and no substantial new themes were emerging during interviews. A total of 58 participants were involved in this study (Table 3).

Table 2: Patient and caregiver characteristics

Patients		Number (total n=24)
Gender	Female	14
	Male	10
Age (years)	<40	2
	41-50	2
	51-60	9
	61-70	6
	>71	5
Mean Age	60 years	
Education level	None	1
	Primary	6
	Secondary	15
	Tertiary	2
Comorbidity	Hypertension	13
	Hypertension + Diabetes	11
NHIF	Active NHIF membership	12
Caregivers		Number (total n=7)
Gender	Female	5
	Male	2

Age (years)	18-40	4
	>40	3
Mean Age	41 years	
Education level	Primary	3
	Secondary	3
	Tertiary	1
Comorbidity	Hypertension	2
	Hypertension + Diabetes	5

173 Table 3: Study participants across levels of care

Participant Role

171

172

	Level 3 Primary	Level 4 & 5	Total
	Health Centres	Hospitals	
Patients (n)	12	12	24
Caregivers (n)	2	5	7
CHPs (n)	4	0	4
Nurses	2	2	4

Pharmacists/Pharmaceutical	3	3	6
technologists (n)			
Community pharmacists (n)	1	3	4
Clinical Officers, Medical doctors, and	2	7	9
medical consultants (n)			
Total (n)	26	32	58

Data Collection

Data were collected between November 2022 and June 2023. First, we conducted non-participant observations spanning 1-3 days in each facility, (DM, PM, RW) structured by a checklist designed to support familiarization with medication procurement and dispensing [Additional file 1]. Observational data were recorded in fieldnotes, subsequently summarized, and cross-checked with facility staff. Medical consultations were not observed.

Second, we conducted in-depth interviews using semi-structured topic guides [Additional file 1] informed by the TFA constructs applied to FDCs for hypertension [Appendix 1]. The interview guide for patients and caregivers focused on experiences with treatment, support in managing hypertension, process of obtaining medication, and familiarity with and perceptions about FDCs. The interview guide for healthcare workers focused on the process of diagnosing and treating hypertension and experiences of and views around use of FDCs to treat hypertension. Interviews were conducted in Swahili/English depending on the participant's preference. Patient and

caregiver interviews were conducted by DM, mainly in Swahili. Interviews with healthcare workers were conducted by DM and RW (social scientists experienced in qualitative research) in English or Swahili. Interviews were conducted in person in a private room at each facility, with only the researcher(s) and participant present. Interviews lasted 15-84 minutes and were audio recorded with participants' consent. During data collection and analysis reflective meetings were held with the broader research team, composed of researchers with diverse backgrounds and experience (public health, medicine, pharmacy) to discuss interpretation of emergent findings and iteratively inform data collection. Audio data were transcribed verbatim and translated into English where necessary. Transcripts were checked for accuracy, translations reviewed, and transcripts imported into NVIVO 12 (QSR International, Australia) for analysis.

Data analysis

We used an abductive thematic analysis approach (26), which builds on 'grounded theory' approaches but explicitly allows for framing of analysis with reference to existing theory, with the aim of fostering conceptual innovation. This involved reading transcripts and identifying initial themes of relevance to the research aim through open coding. Initial themes were then compared with TFA constructs and used to develop a coding framework which was applied across the transcripts, adapted iteratively as needed. Two researchers independently coded a set of five transcripts to ensure inter-coder reliability. Themes were then charted across the seven TFA constructs. The Standards for Reporting Qualitative Research(SRQR) guidelines (27) were followed in our reporting (additional file 2).

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Results In our research we found that the only FDC available in the public sector in Kiambu County during the study period was a dual therapy FDC of losartan (an angiotensin receptor blocker (ARB)) + hydrochlorothiazide (a diuretic). Of the 24 patients interviewed, seven were currently prescribed this FDC. Patient interview data therefore includes both anticipated (n=17) and experienced (n=7) cognitive and emotional responses to FDCs for hypertension. We present key themes affecting acceptability of FDCs for patients and caregivers, and then for healthcare workers, according to the TFA domain to which they relate. Only TFA domains for which there was evidence from our study of key themes related to acceptability are presented in our results. Acceptability of FDC treatment for hypertension for patients and caregivers Affective attitude: FDCs as a means of reducing treatment burden Data from patient and caregiver interviews suggested a positive perception of FDCs as a means of reducing overall burden associated with taking FDCs compared with taking multiple singlemolecule pills. The perception of FDCs as a means of reducing treatment burden was related to the reduction in the burden of obtaining and taking multiple pills, including the time and effort needed to obtain separate pills if they were not available at the public pharmacy, the cognitive work of remembering the correct daily medication schedule and planning ahead to take medication supplies if travelling, the physical discomfort of taking several tablets, and cost. For example:

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

"It would be better than what I'm getting now, separate pills. If it were possible to combine all these medicines together, that would be great... it would save me time of having to look for the other medicines [Individual medicines]." [Patient 17] A combined pill was seen as more convenient - 'you take it once and off you go' [Patient 01] and easier than taking multiple tablets that can feel 'stuck' in the throat; 'when you take one [pill] it's good because it will make the work of swallowing [medicines] easier" [Patient 02]. It was also seen as less costly: "buying the medicine when it's one [combined], it's not like buying three [separate pills]. One is much cheaper to buy than buying three' [Caregiver 07]. The potential role of FDCs in reducing the burden of taking many pills was particularly highlighted by patients with comorbidities. For example, a patient with hypertension, diabetes and HIV noted that when taking multiple medications for different conditions 'you are in trouble because you don't know if you should take them all at once', and that if taking an FDC for hypertension 'the luggage of taking a lot of medicine has been reduced' [Patient_11]. A patient with hypertension and diabetes explained misgivings about ingesting large volumes of 'chemicals' when taking multiple pills, and expressed preference for FDC treatment to reduce the volume of chemicals introduced to the body through separate pills, echoing concerns of several patients that taking multiple medications could be 'harmful' to the body. Intervention coherence: Limited awareness hampering understanding Overall, the extent to which patients and caregivers understand FDCs, or hypertension treatment generally, is low. This is in part due to a lack of information about the concept (with the exception of a small number of patients who had prior experience of FDCs in treatment of other conditions such as HIV or diabetes). Some patients taking the losartan + hydrochlorothiazide combination

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

were unaware that their medication was an FDC. Most patients were not familiar with the medication they were currently taking, for example knowing the name (e.g., losartan) or class (e.g., ARB). Only one patient could describe in simple terms how their antihypertensive medication worked. Some expressed misunderstandings of why an FDC would be effective, suggesting that FDCs create a synergistic effect due to the drugs being combined, for example: "I think it can work faster when it is one pill than the other ones [separate pills]." [Patient 24]. Discussing prospective acceptability, patients emphasized the importance of the concept of combined medications being clearly explained so that patients understood why the number of medicines in their prescription was reduced, for example "it will be best to explain to the patients that the drugs have been combined into one pill because they must have questions...why would I take one instead of three tablets as I was taking?" [Patient 13] Deferral of decision making to healthcare workers Our interviews with patients and caregivers revealed a key theme affecting FDC acceptability that did not fit neatly under any of the TFA domains - a very strong trust in and deferral to healthcare workers. The interviews suggested a belief that knowledge and decisions about medications are the responsibility of healthcare workers and should not be questioned: "A patient cannot do research. Their doctor does the research and tells them that if they take this medication, it has no side effects or something of the sort. So, we [patients] wait for the decision from the doctor" [Patient_19]

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Some patients also noted that they trusted government facility staff to prioritize patients' best interests in prescription decisions, unlike in the private sector where they felt staff may prioritize financial profits. Perceived effectiveness: no concerns about effectiveness of FDC treatment Patients and caregivers did not express concerns about effectiveness of FDCs compared with single molecules, instead anticipating that their doctor would prescribe effective medication based on knowledge of their condition, reinforcing the importance of trust in healthcare workers to make decisions about medications. This finding of no concern is noteworthy as it indicates that patients did not doubt the effectiveness of FDC treatment. Acceptability of FDC treatment for hypertension for healthcare workers Affective attitude: FDCs as a means of reducing treatment burden Healthcare workers' affective attitude about FDCs was also related to perceived reduced burden associated with FDCs compared with multiple single-molecule pills, although healthcare workers identified a wider range of drivers of this burden, considering both burden for the patients and for themselves and the health system. For instance, FDCs were perceived as a treatment approach that could support patient treatment adherence by reducing the likelihood that one individual medication would be unavailable: if we are to be able to package all... drugs in one pill... then I think patients would like it...the compliance is much better and the other side [with separate pills] you know

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

sometimes this drug is over [supply run out] then they only have to use this one..." [Medical Officer 01] Reduction in the number of pills required was again particularly important for when healthcare workers considered patients with co-morbidities. In addition to reducing practical burdens associated with taking multiple pills, FDCs were seen to confer a psychological benefit to patients, as patients associate taking many pills with a condition being 'serious and it's like they are going to die' however 'when it's few medicines, they feel like their condition is not that serious.' [CHP 01]. Reducing the number of pills through introduction of combined losartan + hydrochlorothiazide was described as having been a 'relief' for patients, who a nurse predicted would welcome other combinations as 'they always look forward to taking fewer drugs' [Nurse 18]. Healthcare workers also perceived FDCs as something that would reduce their own burden by reducing the time and resources needed to educate patients about their treatment when prescribing or dispensing medication. "it's even easier for me as a person who is dispensing to explain a drug when it's in fixed dose combination as opposed to explaining like three different drugs to a patient who is not getting it" [Pharmacist 07] Intervention coherence: Comparison with FDCs for HIV treatment The concept of FDCs was well understood by all cadres of healthcare workers except by CHPs. For the CHPs interviewed, intervention coherence was similar to that for patients and caregivers.

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

CHPs were unfamiliar with the concept of FDCs, but demonstrated understanding after neutral explanation by the interviewer, showing potential for intervention coherence if educational support is provided. CHPs noted a similarity with FDCs used in the treatment of HIV, suggesting that familiarity with FDCs for HIV might inform intervention coherence, and thus acceptability, for FDCs for hypertension. For example: "Just like they did with HIV, they used to prescribe so many medicines, these days they give out one, which is good." [CHP 02] Ethicality: FDCs as cause of inequality in access to or affordability of treatment Healthcare workers' value systems prioritised equitable distribution of treatment benefits to as many patients as possible. While the anticipated reduction in burden of FDCs fit well with this value system, FDCs were often perceived to be costlier, and possibly not suitable for all patients, raising ethical concerns regarding how best to distribute limited financial resources to benefit the most patients: " a fixed dose, you find some are taking this, some are not... the best thing is to have them separate so that I can serve these two branches of clients at the same time." [Pharmacist 17] Further, healthcare workers felt ethically obligated to prescribe consistently available and affordable medication, and therefore expressed reluctance to prescribe FDCs if doing so created financial or logistical barriers to treatment. Perceptions of FDC affordability were influenced by the local context, in which the majority of FDCs except losartan + hydrochlorothiazide were only available in the private sector at relatively high cost. Some healthcare workers had experienced

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

an initiative introducing FDC of lisinopril + hydrochlorothiazide at subsidized cost in selected higher-level facilities for a fixed time period (28) and observed that the FDC became unaffordable and difficult to locate when the initiative ended, for example: "In the hospital [it was sold] at Ksh. 200 or 300. The same drug outside, in the chemist, would be almost Ksh. 1000. Then sustainability of that supply was not there...the prescriber prescribes and then the patient comes two, three times and they're like 'I can't find this medicine out there'...they're going to switch to a more readily available molecule" [Pharmacist 04] Perceived effectiveness: FDCs as a means to improve treatment adherence, but with limitations Healthcare worker interview data demonstrated an overall attitude that FDC treatment would be more effective in achieving blood pressure control than separate pills. This was due to perception of FDCs as simpler and more likely to be taken as prescribed, as explained by a pharmacist: "They're standardized in a way... as opposed to previously having a particular pill where the patient was forced to split [it] into two, and you are not sure whether the patient is going to achieve that ...the fixed dose, because they come already prepackaged, and a single tablet has that particular concentration of both drugs... It makes the plasma concentration of that particular drug.... within the required range to achieve that effect that is desired" [Pharmacist 08] However, the perceived effectiveness of FDCs was tempered by the perception of FDCs as "inflexible", in particular that the combined nature of FDCs means that they do not allow for dose

titration of individual drug components, or the identification of which individual component may be causing any side effects.

"some are dosages issues... like the Losartan H. Maybe you need a higher dose of HCTZ (hydrochlorothiazide), but in FDC it's around 12.5mg. The second thing is concerning what we call allergies (side effects) ... There are those people (patients) who come and complain... So sometimes if you have FDC, you don't know whether it is the first drug, the second drug or third drug that has an issue. [Clinical officer 19]

Self-efficacy: Capacity building as crucial to supporting FDC implementation

Familiarity with FDCs varied across cadres of health workers in our study. While physicians working in higher-level facilities had some experience with FDCs, in lower-level facilities, clinicians had experience only indirectly through prescriptions of patients referred from higher level facilities. Data from clinical officers and nurses, who were required to prescribe medications in lower-level facilities, highlighted the lack of awareness of hypertension medications generally, 'most of us we don't have that knowledge' [Nurse_02], and of FDCs in particular, which may undermine levels of self-efficacy in prescribing FDCs. As described by one clinical officer:

"so, one thing we need to do in terms of support is training! Training! Training! That is number one. You need to let everyone know that there are combinations [FDCs]. I might be knowing a few but not every other drug. You might tell me of some combination [FDCs] and I ask you, "When was it launched in Kenya? How long has it been in use?" So, we need training" [Clinical officer 19]

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

Discussion We applied the TFA (29) to evaluate acceptability of FDC treatment, for patients with hypertension, their caregivers and healthcare workers at facilities in Kiambu County. Our results have implications for efforts to improve implementation of FDCs, as well as for the application of the TFA to similar research. Overall, we found that acceptability of FDCs is potentially high, driven by the perceived capacity of FDCs to reduce treatment burden for patients and healthcare workers. The perception of FDCs as a means of reducing treatment burden is supported by evidence of the positive impact on treatment adherence (30-32) (33), and reducing therapeutic inertia (34), and should therefore be promoted by any efforts to improve uptake of FDCs in Kenya. We also found that patients defer to health workers' understanding of and decisions on treatment. Deferral of patients to health professionals, or trust in health professionals, is not unusual, (35) and is likely helpful in promoting uptake of evidence-based medicine, including in relation to combination therapy for cardiovascular disease (36). In our study, we found that deferral to healthcare workers was sometimes accompanied by misconceptions among patients about hypertension treatment (e.g., that an FDC acts on the system more quickly than individual molecules). Knowledge among patients about their medication is crucial to improving treatment adherence and reducing poor health outcomes (37, 38). Efforts to improve effective implementation of FDCs and hypertension treatment generally should consider improving patient awareness of the mechanisms involved, building on trust in healthcare workers by giving

them a key role in delivering awareness-raising campaigns.

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

The deferral of patients to health workers also clearly highlights the importance of ensuring acceptability of FDCs among health workers, both to promote prescription of FDCs and knowledge sharing to patients. Like previous studies on FDCs, we found that acceptability among health workers is likely to be impacted by concerns about FDCs as "inflexible" (for identifying causes of side effects and dose titration) (34, 39-42), intervention coherence, and feelings of selfefficacy, or capacity to appropriately prescribe and support adherence to FDCs (43-45). Efforts to improve implementation of FDCs should therefore consider strengthening knowledge and capacity of health workers of all cadres, including through dissemination of and training in clinical treatment guidelines. Training may focus on the use of FDCs with patients who have shown tolerance to constituent drugs (21, 39), to reduce concerns about side effects. Strengthening capacity of lower cadre health workers will be particularly important where growing integration of NCDs in primary care shifts new responsibility for treatment prescription and support to these cadres. Capacity strengthening initiatives should be continuous rather than "one-off", possibly incorporating annual refreshers or updates similar to those applied in HIV management training (46-49).Another major driver of acceptability of FDCs among health workers was consistent availability and affordability of this treatment option. While this may seem an obvious pre-requisite for implementation, key health system enablers of implementation are often overlooked by implementation trials of hypertension treatment, including of FDCs (18). Any effort to improve awareness and capacity among patients and health workers must be complemented by work to promote prioritisation of low cost generic FDCs in guidelines, county procurement, and reimbursement schemes. The case for prioritisation can be supported by evidence that FDCs are

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

more cost effective to implement compared to usual care (multiple single-molecule pills) (50), with potential cost savings to the health system attributed to better BP control and reduced hospital visits (51). Finally, our study provides insights for the application of the TFA to research on FDCs or other treatment approaches for NCDs, and for future refinement of the TFA. We found the TFA enabled a granular assessment of acceptability, and highlighted inter-relationships between domains, particularly the influence of anticipated burden on other domains. The ethicality domain, defined as 'the extent to which FDC treatment has a good fit with patients' value systems' was challenging to operationalise with patients and caregivers, although it was a clearly conceptualized domain among health workers reflecting on their role in delivering care. This may be because in the space of the interview, patients did not easily identify or reflect on their own value system in relation to treatment, and replacement of multiple single molecules with FDC treatment was a sufficiently similar fit to not provoke reflection or comment. A recent review of research that applied the TFA to acceptability of HIV prevention and treatment measures noted that ethicality was not reported as a distinct construct, and suggested that future refinement of the TFA reconsider the role of value systems and measurement of this dimension (52). We suggest that ethicality remains a relevant construct but may be more readily identified by people receiving interventions where the intervention more dramatically disrupts value systems than where it has a good fit or is less 'seen'. We also found that trust in healthcare workers played a significant role in informing acceptability and was distinct from the existing TFA domains. This theme merits exploration in future studies on treatment approaches for NCDs, and in refinement of the TFA.

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

Limitations This study was conducted in public facilities in one county in Kenya and therefore was not intended to be nationally representative of the Kenyan population. However, it includes a diverse, purposively selected participant sample of patients, caregivers, CHPs, nurses, pharmacists, clinical officers and medical doctors drawn from different levels of care, strengthening transferability. Conclusion FDCs are a potentially acceptable treatment approach for hypertension in Kenya. Efforts to improve acceptability and thus implementation of FDCs in Kenya should consider improving hypertension patients and caregivers understanding of treatment and strengthening the capacity of all health worker cadres to appropriately prescribe, inform about, and support adherence to FDCs. These efforts must align with work to address upstream health system factors such as poor availability and affordability, which will impede implementation. The TFA provides an appropriate framework for exploring the multifaceted nature of FDC acceptability, allowing incorporation of multiple stakeholder perspectives. List of abbreviations CHPs: Community health promoters CVD: Cardiovascular diseases EML: Essential medicines list FDCs: Fixed dose combinations

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

LMICs: Low- and middle-income countries NCDs: Non communicable diseases NHIF: National Health Insurance Fund TFA: Theoretical framework of acceptability Declaration **Ethics** This study was approved by Kenya Medical Research Institute's scientific and ethics review unit (SERU) (Approval NO: KEMRI/RES/7/3/1), National Commission of Science and Technology (NACOSTI) (Approval NO: NACOSTI/P/22/21524) and London School of Hygiene and Tropical Medicine Research Ethics Committee (28062). Permissions were also granted by the county government and each facility before commencement of the study. Written informed consent was obtained from all participants. Researchers took care to ensure that potential participants understood that participation was optional, and that participation or non-participation in the study would not affect the care which patients received. Consent for publication Not applicable.

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

Availability of materials and data The dataset used during this study is available from the authors upon reasonable request and permission from the KEMRI Wellcome Trust Research and Governance Committee. Competing interests All the authors declare that they have no competing interests. Funding This work was supported by UKRI Future Research Leader Fellowship grant awarded to AM by the UK Research and Innovation fund, MR/T042508/1. The funding sources had no role in the study design, writing of the report and in the decision to submit the manuscript for publication. Author contribution DM: Investigation; analysis, writing (review and editing); project administration; MG: Conceptualization; review and editing; JN: Writing (review and editing); project administration PM: Conceptualization; formal analysis; project administration; RW: Conceptualization; investigation; formal analysis; writing (review and editing); AM: Conceptualization; investigation; formal analysis; writing (review and editing); funding; project administration. Acknowledgement We would also like to acknowledge all the healthcare workers, patients and caregivers who participated in the study. We also thank Hillary Koros for supporting with data collection.

References

495

- 496 1. World Health Organization. Cardiovascular diseases (CVDs) 2021 [cited 2023 15/09/2023].
- 497 Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
- 498 (cvds)#:~:text=At%20least%20three%2Dquarters%20of,with%20risk%20factors%20for%20CVDs.
- 499 2. Mohamed SF, Mutua MK, Wamai R, Wekesah F, Haregu T, Juma P, et al. Prevalence, awareness,
- treatment and control of hypertension and their determinants: results from a national survey in Kenya.

 BMC public health. 2018;18(3):1-10.
- 3. Ministry of Health. KENYA STEPwise SURVEY FOR NON COMMUNICABLE DISEASES RISK FACTORS
- 2015 REPORT 2015 [cited 2023 30/10/2023]. Available from: http://www.nutritionhealth.or.ke/wp-
- 504 <u>content/uploads/Downloads/Kenya%20STEPwise%20Survey%20for%20Non-</u>
- 505 Communicable%20Diseases%20Risk%20Factors%20Report%202015.pdf.
- 506 4. Lotfizadeh A, Palafox B, Takallou A, Balabanova D, McKee M, Murphy A. Factors associated with 507 the availability and affordability of essential cardiovascular disease medicines in low-and middle-income
- 508 countries: A systematic review. PLOS Global Public Health. 2022;2(3):e0000072.
- 509 5. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive
- 510 drug treatments: longitudinal study of electronically compiled dosing histories. Bmj.
- 511 2008;336(7653):1114-7.
- 6. Cohn J, Bygrave H, Roberts T, Khan T, Ojji D, Ordunez P. Addressing failures in achieving
- hypertension control in low-and middle-income settings through simplified treatment algorithms. Global
- 514 Heart. 2022;17(1).
- 515 7. Lebeau J-P, Cadwallader J-S, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and
- definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC
- family practice. 2014;15(1):1-10.
- 8. Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive
- treatment. Circulation Research. 2019;124(7):1113-23.
- 520 9. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations
- of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
- 522 10. Webster R, Salam A, De Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple
- 523 combination antihypertensive medication vs usual care for blood pressure control in patients with mild
- to moderate hypertension in Sri Lanka: a randomized clinical trial. Jama. 2018;320(6):566-79.
- 525 11. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination
- antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort
- 527 study. PLoS medicine. 2018;15(6):e1002584.
- 528 12. Sarfo FS, Mobula LM, Burnham G, Ansong D, Plange-Rhule J, Sarfo-Kantanka O, et al. Factors
- associated with uncontrolled blood pressure among Ghanaians: evidence from a multicenter hospital-
- 530 based study. PloS one. 2018;13(3):e0193494.
- 531 13. van der Linden EL, Agyemang C, van den Born BJH. Hypertension control in sub-Saharan Africa:
- 532 Clinical inertia is another elephant in the room. The Journal of Clinical Hypertension. 2020;22(6):959.
- 533 14. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination
- therapies for hypertension: a meta-analysis of health care costs and adherence. The Journal of Clinical
- 535 Hypertension. 2011;13(12):898-909.
- 536 15. World Health Organization. Guideline for the pharmacological treatment of hypertension in adults
- 537 2021 [cited 2023 15/09/2023]. Available from:
- 538 https://apps.who.int/iris/bitstream/handle/10665/344424/9789240033986-eng.pdf.
- 539 16. Ministry of Health. Kenya Essential Medicines List. Ministry of Health; 2023.

- 540 17. Ministry of Health. KENYA NATIONAL GUIDELINES FOR CARDIOVASCULAR DISEASES
- 541 MANAGEMENT 2018 [cited 2023 15/09/2023]. Available from:
- 542 http://guidelines.health.go.ke:8000/media/Kenya National Guidelines for Cardiovascular Diseases M anagement.pdf.
- 544 18. Webster R, Murphy A, Bygrave H, Ansbro É, Grobbee DE, Perel P. Implementing fixed dose
- 545 combination medications for the prevention and control of cardiovascular diseases. Global Heart.
- 546 2020;15(1).
- 547 19. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of
- reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.
- 549 20. Jafar TH, Tavajoh S, de Silva HA, Naheed A, Jehan I, Kanatiwela de Silva C, et al. Post-intervention
- acceptability of multicomponent intervention for management of hypertension in rural Bangladesh,
- Pakistan, and Sri Lanka-a qualitative study. PloS one. 2023;18(1):e0280455.
- 552 21. Murphy A, Willis R, Ansbro É, Masri S, Kabbara N, Dabbousy T, et al. Implementation of fixed-dose
- 553 combination therapy for secondary prevention of atherosclerotic cardiovascular disease among Syrian
- refugees in Lebanon: a qualitative evaluation. BMC Health Services Research. 2022;22(1):1-12.
- 555 22. Paparini S, Papoutsi C, Murdoch J, Green J, Petticrew M, Greenhalgh T, et al. Evaluating complex
- 556 interventions in context: systematic, meta-narrative review of case study approaches. BMC Medical
- 557 Research Methodology. 2021;21(1):225.
- 558 23. Kenya National Bureau of Statistics. The Kenya Poverty Report: Based on the 2021 Kenya
- 559 Continuous Household Survey. Nairobi: Kenya National Bureau of Statistics; 2023.
- 560 24. Kenya National Bureau of Statistics. COUNTY STATISTICAL ABSTRACT: KIAMBU COUNTY 2015
- 561 [cited 2023 30/10/2023]. Available from: https://www.knbs.or.ke/download/kiambu/.
- 562 25. Kenya National Bureau of Statistics. 2019 Kenya Population and Housing Census Volume I:
- Population by County and Sub County. 2019 November 2019.
- 564 26. Timmermans S, Tavory I. Theory construction in qualitative research: From grounded theory to
- abductive analysis. Sociological theory. 2012;30(3):167-86.
- 566 27. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research:
- a synthesis of recommendations. Academic medicine. 2014;89(9):1245-51.
- 568 28. Ngariko GW. Impact of the Healthy Heart Africa Program on the Adequacy of Blood Pressure
- 569 Control in Kiambu County: University of Nairobi; 2021.
- 570 29. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of
- reviews and development of a theoretical framework. BMC health services research. 2017;17(1):1-13.
- 572 30. Bramlage P, Schmidt S, Sims H. Fixed-dose vs free-dose combinations for the management of
- 573 hypertension—An analysis of 81 958 patients. The Journal of Clinical Hypertension. 2018;20(4):705-15.
- 574 31. Czarnecka D, Koch E, Gottwald-Hostalek U. Benefits of a fixed-dose combination of bisoprolol and
- amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Current
- 576 Medical Research and Opinion. 2015;31(5):875-81.
- 577 32. Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus
- 578 free-equivalent combination therapies on adherence for hypertension: a meta-analysis. The Journal of
- 579 Clinical Hypertension. 2018;20(5):902-7.
- 580 33. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in
- 581 hypertension: systematic review and meta-analysis. Archives of medical science. 2018;14(5):1125-36.
- 582 34. DiPette DJ, Skeete J, Ridley E, Campbell NR, Lopez-Jaramillo P, Kishore SP, et al. Fixed-dose
- 583 combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and
- policy implications. The Journal of Clinical Hypertension. 2019;21(1):4.
- 585 35. Gale NK, Greenfield S, Gill P, Gutridge K, Marshall T. Patient and general practitioner attitudes to
- 586 taking medication to prevent cardiovascular disease after receiving detailed information on risks and
- 587 benefits of treatment: a qualitative study. BMC Family Practice. 2011;12(1):1-10.

- 36. IU H, MY M, P G. Patients' knowledge about medicines improves when provided with written
- compared to verbal information in their native language. Plos one. 2022;17(10):e0274901.
- 590 37. Bosworth HB, Fortmann SP, Kuntz J, Zullig LL, Mendys P, Safford M, et al. Recommendations for
- 591 providers on person-centered approaches to assess and improve medication adherence. Journal of
- 592 general internal medicine. 2017;32:93-100.
- 593 38. Takaki H, Abe T, Hagihara A. Physicians' and pharmacists' information provision and patients'
- 594 psychological distress. Journal of Interprofessional Care. 2017;31(5):575-82.
- 595 39. Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, et al. Two-drug fixed-dose
- 596 combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy,
- safety, and cost. The Journal of Clinical Hypertension. 2020;22(10):1769-79.
- 598 40. Godman B, McCabe H, D Leong T, Mueller D, Martin AP, Hoxha I, et al. Fixed dose drug
- combinations—are they pharmacoeconomically sound? Findings and implications especially for lower-and
- 600 middle-income countries. Expert review of pharmacoeconomics & outcomes research. 2020;20(1):1-26.
- 601 41. Gupta YK, Ramachandran SS. Fixed dose drug combinations: Issues and challenges in India. Indian journal of pharmacology. 2016;48(4):347.
- 603 42. Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons
- 604 learned. The Lancet. 2017;389(10073):1066-74.
- 605 43. Singh A, Dhaneria S, Gupta D. Physician's knowledge, attitude and practice of fixed drug
- 606 combinations: Can we recognize the lacunae? Journal of Family Medicine and Primary Care.
- 607 2022;11(5):2019.
- 608 44. Gupta R, Malhotra P, Malhotra A. Assessment of knowledge, attitude, and practices about
- 609 prescribing fixed dose combinations among doctors-An observational study. National Journal of
- Physiology, Pharmacy and Pharmacology. 2018;8(3):347-52.
- 611 45. Gupta R, Malhotra A, Malhotra P. Assessment of rational use of fixed dose combinations in
- 612 hypertension in a tertiary care teaching hospital in north India. International Journal of Advances in
- 613 Medicine. 2018;5(5):1263.
- 614 46. Frieden TR, Varghese CV, Kishore SP, Campbell NR, Moran AE, Padwal R, et al. Scaling up effective
- 615 treatment of hypertension—a pathfinder for universal health coverage. The Journal of Clinical
- 616 Hypertension. 2019;21(10):1442-9.
- 617 47. Okoroafor SC, Christmals CD. Health Professions Education Strategies for Enhancing Capacity for
- 618 Task-Shifting and Task-Sharing Implementation in Africa: A Scoping Review. Journal of Continuing
- 619 Education in the Health Professions. 2022:10.1097.
- 620 48. Crowley T, Mayers P. Trends in task shifting in HIV treatment in Africa: Effectiveness, challenges
- and acceptability to the health professions. African journal of primary health care & family medicine.
- 622 2015;7(1):1-9.
- 623 49. Vedanthan R, Bernabe-Ortiz A, Herasme OI, Joshi R, Lopez-Jaramillo P, Thrift AG, et al. Innovative
- 624 approaches to hypertension control in low-and middle-income countries. Cardiology clinics.
- 625 2017;35(1):99-115.
- 50. Lung T, Jan S, de Silva HA, Guggilla R, Maulik PK, Naik N, et al. Fixed-combination, low-dose, triple-
- 627 pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri
- 628 Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. The Lancet Global Health.
- 629 2019;7(10):e1359-e66.
- 630 51. Putignano D, Orlando V, Monetti VM, Piccinocchi G, Musazzi UM, Piccinocchi R, et al. Fixed versus
- free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in
- 632 Italy. Patient preference and adherence. 2019:1961-9.
- 633 52. Ortblad KF, Sekhon M, Wang L, Roth S, van der Straten A, Simoni JM, et al. Acceptability
- assessment in HIV prevention and treatment intervention and service delivery research: a systematic
- review and qualitative analysis. AIDS and Behavior. 2023;27(2):600-17.

Appendix 1

636

637

Theoretical Framework of Acceptability constructs (19) applied to FDCs for hypertension

Construct	Meaning	Meaning for acceptability of FDC treatment for hypertension
		for patients, caregivers, and healthcare workers
Affective	How an individual	How patients, caregivers and healthcare workers feel about
attitude	feels about the	FDC treatment
	intervention	
Burden	The perceived	The perceived amount of effort required for patients to use
	amount of effort	FDCs according to their prescribed use.
	that is required to	The perceived amount of effort required by caregivers to
	participate in the	support patients to use FDC treatment
	intervention	The perceived amount of effort required by healthcare workers
		to treat hypertensive patients using FDCs
Ethicality	The extent to which	The extent to which FDC treatment has a good fit with
	the intervention has	patients'/caregivers'/healthcare workers' value systems
	good fit with an	
	individual's value	
	system	
Intervention	The extent to which	The extent to which patients/caregivers understand FDC
coherence	the individual	treatment and how it works (i.e. understand the concept of
	understands the	combining separate hypertension medications in one pill, rather

	intervention and	than understanding the mechanism of action of each	
	how it works	medication)	
		The extent to which healthcare workers understand FDC	
		treatment and how it works	
Opportunity	The extent to which	The extent to which benefits, values or profits must be given	
costs	benefits, values or	up:	
	profits must be given	- by patients to adhere to FDC treatment	
	up to engage in the	- by caregivers to support patients to adhere to FDC treatment	
	intervention	- by healthcare workers to use FDCs to treat patients	
Perceived	The extent to which	The extent to which patients/caregivers/healthcare workers	
effectiveness	the intervention is	perceive FDC treatment as likely to achieve management of	
	perceived as likely to	hypertension	
	achieve its purpose		
Self-efficacy	The participant's	Patient's confidence that they can adhere to FDC treatment	
	confidence that they	Caregivers' confidence that they can support patients to adhere	
	can perform the	to FDC treatment	
	behaviour(s)	Healthcare workers' confidence that they can use FDCs to treat	
	required to	patients	
	participate in the		
	intervention		